Paper32065631
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
Cirrincione LR and 9 others. J Antimicrob Chemother, 2020. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. Papers, record 32065631. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32065631
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| Pharmaceutical Preparations | Major topic |
| Pre-Exposure Prophylaxis | Major topic |
| Transgender Persons | Major topic |
| Adult | |
| Emtricitabine | |
| Female | |
| Hormones | |
| Humans | |
| Tenofovir | |
| Male |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K23 AI134307 | NIAID NIH HHS | United States | K23AI134307 | PubMed and NIH | NIH RePORTER |
| R01 AI124965 | NIAID NIH HHS | United States | R01AI124965 | PubMed and NIH | NIH RePORTER |
| R01 HD085887 | NICHD NIH HHS | United States | R01HD085887 | PubMed and NIH | NIH RePORTER |
| UM1 AI106701 | NIAID NIH HHS | United States | UM1AI106701 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03270969 | A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women | Derived from the trial | Yes |
Source ClinicalTrials.gov
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21091279 | Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. | N Engl J Med | 2010 | https://conductscience.org/library/papers/21091279 | PubMed |
| 2 | 27431475 | Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. | J Int AIDS Soc | 2016 | https://conductscience.org/library/papers/27431475 | PubMed |
| 3 | 31692269 | Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. | J Int AIDS Soc | 2019 | https://conductscience.org/library/papers/31692269 | PubMed |
| 4 | 25409469 | Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25409469 | PubMed |
| 5 | 22972843 | Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22972843 | PubMed |
| 6 | 17519400 | Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. | J Clin Pharmacol | 2007 | https://conductscience.org/library/papers/17519400 | PubMed |
| 7 | 31298497 | Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. | J Int AIDS Soc | 2019 | https://conductscience.org/library/papers/31298497 | PubMed |
| 8 | 23111578 | Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? | J Acquir Immune Defic Syndr | 2013 | https://conductscience.org/library/papers/23111578 | PubMed |
| 9 | 30963179 | Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30963179 | PubMed |
| 10 | 18025112 | Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18025112 | PubMed |
| 11 | 21118913 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. | J Antimicrob Chemother | 2011 | https://conductscience.org/library/papers/21118913 | PubMed |
| 12 | 14643879 | Limitations of direct estradiol and testosterone immunoassay kits. | Steroids | 2003 | https://conductscience.org/library/papers/14643879 | PubMed |
| 13 | 25065857 | Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/25065857 | PubMed |
| 14 | 27429187 | Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. | J Acquir Immune Defic Syndr | 2016 | https://conductscience.org/library/papers/27429187 | PubMed |
| 15 | 15290871 | P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. | Pharm Res | 2004 | https://conductscience.org/library/papers/15290871 | PubMed |
| 16 | 16828350 | Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. | J Chromatogr B Analyt Technol Biomed Life Sci | 2006 | https://conductscience.org/library/papers/16828350 | PubMed |
| 17 | 28075632 | Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples. | Am J Public Health | 2017 | https://conductscience.org/library/papers/28075632 | PubMed |
| 18 | 24317955 | Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. | Ann Behav Med | 2014 | https://conductscience.org/library/papers/24317955 | PubMed |
| 19 | 23274933 | Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. | J Acquir Immune Defic Syndr | 2013 | https://conductscience.org/library/papers/23274933 | PubMed |
| 20 | 28225438 | Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis. | J Acquir Immune Defic Syndr | 2017 | https://conductscience.org/library/papers/28225438 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42439052 | Special Issue: New Horizons in HIV and Reproductive Health Research: HIV Acquisition and Reproductive Health in Key Populations. | Am J Reprod Immunol | 2026 | https://conductscience.org/library/papers/42439052 | PubMed |
| 40390323 | No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. | J Int AIDS Soc | 2025 | https://conductscience.org/library/papers/40390323 | PubMed |
| 40195242 | Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. | J Int AIDS Soc | 2025 | https://conductscience.org/library/papers/40195242 | PubMed |
| 38421210 | Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial. | Clin Transl Sci | 2024 | https://conductscience.org/library/papers/38421210 | PubMed |
| 38312459 | Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial. | Transgend Health | 2024 | https://conductscience.org/library/papers/38312459 | PubMed |
| 37681452 | Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study. | J Antimicrob Chemother | 2023 | https://conductscience.org/library/papers/37681452 | PubMed |
| 37261664 | Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/37261664 | PubMed |
| 36416569 | Inclusion of Transgender and Gender Diverse People in Phase III Trials: Examples from HIV Pharmacologic Prevention Studies. | Clin Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36416569 | PubMed |
| 35943868 | Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. | AIDS Res Hum Retroviruses | 2022 | https://conductscience.org/library/papers/35943868 | PubMed |
| 35815666 | Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35815666 | PubMed |
| 35815468 | Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. | AIDS Res Hum Retroviruses | 2022 | https://conductscience.org/library/papers/35815468 | PubMed |
| 35687813 | Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review. | AIDS Patient Care STDS | 2022 | https://conductscience.org/library/papers/35687813 | PubMed |
| 35285974 | Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. | Br J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35285974 | PubMed |
| 33404067 | Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus. | Pharmacotherapy | 2021 | https://conductscience.org/library/papers/33404067 | PubMed |
| 32724080 | Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics. | Sci Rep | 2020 | https://conductscience.org/library/papers/32724080 | PubMed |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE | CHEMBL1486 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1486 | ChEMBL |
| EMTRICITABINE, (+/-)- | CHEMBL161381 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL161381 | ChEMBL |
| EMTRICITABINE | CHEMBL885 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL885 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32065631
GET https://conductscience.org/api/papers/v1/32065631/references?page=2